Brind.

Johnson & Johnson R&D background cited in Onicor CEO appointment

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Onicor appointed Piet De Doncker as its new Chief Executive Officer. Dr. De Doncker previously held a leading role in developing itraconazole pulse therapy for onychomycosis at Janssen Research & Development in Beerse, Belgium, which is part of Johnson & Johnson. He also held senior R&D leadership positions at Johnson & Johnson, including leading its dermatology R&D team.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The appointment highlights the transfer of specialized antifungal and dermatology drug development expertise from Johnson & Johnson's R&D operations to Onicor. Dr. De Doncker's background includes work on a widely used treatment option for fungal nail infections.

From manilatimes.net

Who's involved

  • Johnson & JohnsonOwns Janssen Research & Development in Beerse, where Dr. De Doncker worked.
  • BeerseMunicipality where Janssen Research & Development is located.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped